Search

Author/Creator Yimer, H.

1. ACALABRUTINIB PLUS PEMBROLIZUMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: A PHASE 1/2 STUDY. (12th June 2019)

Authors:
Witzig, T.E.; Maddocks, K.; de Vos, S.; Lyons, R.; Edenfield, W.; Sharman, J.; Vose, J.; Yimer, H.; Wei, H.; Chan, E.; Patel, P.; Di Simone, C.; Gandhi, M.; Vaughn, J.; Kolibaba, K.; Cheson, B.; Samaniego, F.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
327
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY (SGN35 027 PART B). (23rd June 2022)

Authors:
Lee, H.; Flinn, I. W.; Melear, J.; Ramchandren, R.; Friedman, J.; Burke, J. M.; Linhares, Y.; Raval, M.; Chintapatla, R.; Feldman, T. A.; Yimer, H.; Islas-Ohlmayer, M.; Dean, A.; Rana, V.; Gandhi, M. D.; Renshaw, J.; Gillespie-Twardy, A. L.; Ho, L.; Puhlmann, M.; Guo, W.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
979
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS. (May 2023)

Authors:
Garcia-Manero, G.; Bachiashvili, K.; Griffiths, E.; Traer, E.; Saini, L.; Amin, H.; Zeidan, A.; Mohan, S.; Lübbert, M.; Maness, L.; Foran, J.; Selleslag, D.; Xicoy, B.; Pollyea, D.; Sallman, D.; Al-Kali, A.; Berdeja, J.; Al-Ali, H.; Zhu, N.; Lopez, P. Font
Journal:
Leukemia research
Issue:
Volume 128(2023)Supplement
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗